eClinical Solutions LLC, a global leader in digital clinical software and data services, has introduced its new elluminate AI agents—an intelligent layer seamlessly built into the elluminate ecosystem to advance data automation and decision-making in clinical research.
First showcased at the company’s ENGAGE conference in October, these AI agents integrate into the four core pillars of the elluminate Clinical Data Cloud®—Data Mapping, Data Review, RBQM, and Study Operations. Designed with governed data, explainable AI, and guided human oversight, the new technology aims to define how clinical trials will operate through the next decade.
As Phase III trial data volumes have surged—surpassing 5.9 million data points on average in 2025—eClinical Solutions continues to strengthen its position as a foundational provider for clinical data infrastructure and analytics. The company’s latest innovation reflects its commitment to accelerating discovery through AI-driven hypotheses and human-validated outcomes.
Built on a shared data foundation with robust policies and domain expertise, the AI agents act as intelligent collaborators that can interpret complex clinical trial data in real time. Their functionality spans several areas:
- Data Mapping: Streamlines transformation from raw data to ready datasets through spec generation and validation.
- Data Review: Enhances review efficiency using visualization tools and semi-automated anomaly detection.
- RBQM: Bolsters oversight by generating risk statements, tracking key quality indicators, and recommending mitigations.
- Study Operations: Shortens setup cycles and boosts transparency by analyzing protocols and operational bottlenecks.
Raj Indupuri, CEO and co-founder of eClinical Solutions, said, “We’ve spent over a decade addressing the industry’s data challenges through our elluminate platform. With the introduction of elluminate AI agents, we’re evolving from a data cloud to a data intelligence platform, enabling faster, more insightful decision-making while keeping humans at the core.”
The first rollout of elluminate AI agents is slated for early 2026, following a phased product release. The initiative marks a pivotal step toward enabling faster, smarter, and more transparent clinical trial workflows powered by data and AI.
Explore Health-Tech News for the latest advancements in Healthcare Technology & insightful updates from industry experts!
Source: Businesswire
